Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (451-460 of 602) with videos related to

Pageof 61
Sort By:
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood Cancer Journal|December 12, 2023
Muscle and fat composition in patients with newly diagnosed multiple myelomaNadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, et al.
Blood Advances|August 21, 2023
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
American Journal of Hematology|September 30, 2017
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)Nidhi Tandon, Surbhi Sidana, Angela Dispenzieri, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Frontiers in Endocrinology|July 8, 2022
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal OutcomeEli Muchtar, Matthew T Drake, Nelson Leung, et al.
British Journal of Haematology|November 20, 2020
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myelomaJithma P Abeykoon, David L Murray, Isaiah Murray, et al.
European Journal of Haematology|November 24, 2020
Characterization and prognostic implication of delayed complete response in AL amyloidosisEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|July 19, 2020
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratioEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
Pageof 61

Showing results (451-460 of 602) with videos related to

Sort By:
Pageof 61
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood Cancer Journal|December 12, 2023
Muscle and fat composition in patients with newly diagnosed multiple myelomaNadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, et al.
Blood Advances|August 21, 2023
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
American Journal of Hematology|September 30, 2017
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)Nidhi Tandon, Surbhi Sidana, Angela Dispenzieri, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Frontiers in Endocrinology|July 8, 2022
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal OutcomeEli Muchtar, Matthew T Drake, Nelson Leung, et al.
British Journal of Haematology|November 20, 2020
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myelomaJithma P Abeykoon, David L Murray, Isaiah Murray, et al.
European Journal of Haematology|November 24, 2020
Characterization and prognostic implication of delayed complete response in AL amyloidosisEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|July 19, 2020
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratioEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
Pageof 61